Publications
Page 1 of 4
October 14, 2020
Transparency and reproducibility in artificial intelligence
Breakthroughs in artificial intelligence (AI) hold enormous potential as it can automate complex tasks and go even beyond human performance. In their study, McKinney et al.1 showed the high potential…
Journal: Nature
October 12, 2020
Clinical landscape of oncolytic virus research in 2020
Oncolytic viruses (OVs) are a new class of cancer therapeutics. This review was undertaken to provide insight into the current landscape of OV clinical trials. A PubMed search identified 119…
Journal: Journal for ImmunoTherapy of Cancer
September 25, 2020
pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model
Huntington disease (HD), a devastating hereditary neurodegenerative disorder, is caused by an expansion of a CAG trinucleotide repeat that encodes a polyglutamine (polyQ) tract in the huntingtin (HTT) gene.
Journal: Cell Death & Disease
June 25, 2020
Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)
The recent global pandemic has placed a high priority on identifying drugs to prevent or lessen clinical infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused by Coronavirus disease-2019…
Journal: Journal of Translational Medicine
June 12, 2020
Quantitative Structure–Activity Relationship Models for Predicting Inflammatory Potential of Metal Oxide Nanoparticles
Although substantial concerns about the inflammatory effects of engineered nanomaterial (ENM) have been raised, experimentally assessing toxicity of various ENMs is challenging and time-consuming. Alternatively, quantitative structure–activity relationship (QSAR) models…
Journal: Environmental Health Perspectives
May 26, 2020
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune…
Journal: Leukemia
January 15, 2019
Computational prediction models for assessing endocrine disrupting potential of chemicals
Endocrine disrupting chemicals (EDCs) mimic natural hormones and disrupt endocrine function. Humans and wildlife are exposed to EDCs might alter endocrine functions through various mechanisms and lead to an adverse…
Journal: Journal of Environmental Science and Health, Part C Environmental Carcinogenesis and Ecotoxicology Reviews
May 21, 2018
Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
Huntington Disease (HD) is an incurable autosomal dominant neurodegenerative disorder driven by an expansion repeat giving rise to the mutant huntingtin protein (mHtt), which is known to disrupt a multitude…
Journal: Molecular Neurodegeneration
May 15, 2018
Structural Changes Due to Antagonist Binding in Ligand Binding Pocket of Androgen Receptor Elucidated through Molecular Dynamics Simulations
When a small molecule binds to the androgen receptor (AR), a conformational change can occur which impacts subsequent binding of co-regulator proteins and DNA. In order to accurately study this…
Journal: Frontiers in Pharmacology
April 9, 2018
Loss of the Sigma-1 receptor disrupts pridopidine-induced gene expression
Objective: Investigate the role of S1R in the mechanism of action of pridopidine. Background: Sigma-1 receptor (S1R) is an ER chaperone protein involved in neuromodulation and neuroplasticity. Pridopidine is a…
Page 1 of 4
